ONO-4641 Reduced Number Of Multiple Sclerosis Lesions In Phase II Trial
ONO-4641, an investigational oral drug, reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase two clinical trial to be presented this week at…